Integrated BioPharma, Inc. (INBP) News
Follow Integrated BioPharma, Inc. (INBP) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Integrated BioPharma, Inc. (INBP) FY26 Revenue Falls 19%, Turns to Loss
Integrated BioPharma reported FY26 revenue of $43.9M, down 19.3% YoY, and an operating loss of ~$2.7M vs. $2.0M income in FY25. Q4 revenue was $9.8M, down 31.0% YoY, with a net loss of ~$1.4M.Material DetailsContext by A
EARNINGS | Sep 25, 2026, 09:01 PM UTC
L
Integrated BioPharma Reports Results for its Quarter and Fiscal Year Ended June 30, 2026
HILLSIDE, NJ / / September 25, 2026 / Integrated BioPharma, Inc. OTC:INBP (the "Company" or "INBP") reports its financial results for the quarter and fiscal year ended June 30, 2026.Revenue for the quarter ended June 30,
EARNINGS | Sep 25, 2026, 09:01 PM UTC
L
INTEGRATED BIOPHARMA INC FY 2026: Revenue $43.87M, EPS ($0.09) — 10-K Summary
Integrated Biopharma Inc reported fiscal 2026 results with revenue of $43.87M, down from $54.35M a year earlier, producing a net loss of ($2.84M) and diluted EPS of ($0.09) — a year-over-year decline versus FY 2025 — acc
EARNINGS | Sep 25, 2026, 08:46 PM UTC